Pennytobuck Stock Highlight On Prot, Stem, And Nvo
PROTEONOMIX, INC
PROTEONOMIX, INC. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.
The trip is scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).
Mr. Cohen will also discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
In their release from August 17th, 2010, their recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC., a Nevis Island limited liability company.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomixs operating subsidiary.
To receive additional information about Proteonomix, Inc., please visit the website at http://www.proteonomix.com/
StemCells, Inc. (Nasdaq:STEM) announced the publication of new preclinical data demonstrating STEMs proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury.
This is the first published study to show that human neural stem cells can restore mobility even when administered at time points beyond the acute phase of trauma, suggesting the prospect of treating a much broader population of injured patients than previously demonstrated.
This groundbreaking study, entitled Human Neural Stem Cells Differentiate and Promote Locomotor Recovery in an Early Chronic Spinal Cord Injury NOD-scid Mouse Model, was led by Dr. Aileen Anderson of the Sue and Bill Gross Stem Cell Research Center at the University of California, Irvine (UCI). The paper was published yesterday in the international peer-reviewed journal PLoS ONE, and is available online at http://dx.plos.org/10.1371/journal.pone.0012272.
STEM is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development.
To receive additional information about StemCells, Inc., please visit the website at www.stemcellsinc.com.
Novo Nordisk Inc. (NYSE:NVO) recently reported that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through NVO's existing field sales force.
NVO introduced Vagifem 10 mcg to the U.S. market earlier this year. The new dose replaces Vagifem 25 mcg dose, which was discontinued on July 30, 2010.
About Vagifem
Vagifem is used after menopause to treat menopausal changes in and around the vagina.
Do not start using Vagifem if you: have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, are allergic to Vagifem or any of its ingredients, or think you may be pregnant.
The most commonly reported side effects of Vagifem included: headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, and vaginal yeast infection.
To receive additional information about Novo Nordisk Inc., please visit the website at http://www.novonordisk.com
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
by: Bill Pennyman
Experience Prague's Sights And Sounds Why Should You Get Inexpensive Milwaukee Break To Go To The And More This Year Be At Ease And Enjoy At The Scenic Neighborhoods In Peloponnese For Your Greatest Greek Retreats Be At Ease And Bask In At The Pleasing Places In Halkidiki For Your Best Greece Visits Stocking up Gold for Cataclysm, Add Wow-gold-team.com as Your Favorite Easy Ways To Declutter Your Office And Desktop Using Shampoo And Conditioner Size, Shape And Where To Position Your Pond Lighten Up And Relish At These Scenic Cities In Eastern Aegean For Your Perfect Greece Visits Hot Tub And Spa Enclosures Ways To Get Fun Milwaukee, Ws Escapes To Attend And Much More Right Now Pennytobuck.com Stock Highlights On Payx, Nv, Nwtt Stock Updates From Pennytobuck On Cypb, Wdfc, And Tgmp